LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

DocGo Announces Upcoming Participation at 22nd Annual Needham Virtual Healthcare Conference

April 04, 2023 | Last Trade: US$2.12 0.07 -3.20

NEW YORK / Apr 04, 2023 / Business Wire / DocGo Inc (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that Lee Bienstock, President and Chief Operating Officer will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20 at 2:15PM Eastern Time. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.

About DocGo

DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with Ambulnz by DocGo's integrated medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page